전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved8 programs
AntibodyLimited DatastaleElevation OncologyPhase 1

CYRAMZA® (Ramucirumab, Ramucirumab (CYRAMZA®))

Stomach Neoplasm; Gastrointestinal Neoplasms · Stomach Neoplasm

#StomachNeoplasm#Antibody#Phase1#Popular#monoclonal-antibody+3
Trials 84Status Discontinued
ADCStandard DatabasestaleDaiichi SankyoPhase 2

TDxD (Fam-Trastuzumab Deruxtecan-Nxki, Fam-Trastuzumab Deruxtecan-Nxki (TDxD))

Gastric Cancer; Gastrointestinal Cancer · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#antibody-drug-conjugate#GastricCancer+2
Trials 27Status Recruiting
ADCStandard DatabasestaleMerck Sharp & Dohme LLCPhase 2

R-DXd (Raludotatug Deruxtecan, Raludotatug Deruxtecan (R-DXd))

Gastrointestinal Cancer · Gastrointestinal Cancer

#GastrointestinalCancer#ADC#Phase2#antibody-drug-conjugate#Merck
Trials 9Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

KRAS TCR-Transduced PBL (KRAS TCR-Transduced PBL)

Metastatic Solid Cancers; Colorectal Cancer · Gastrointestinal Carcinoma

#GastrointestinalCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 4Status Recruiting
ADCLimited DatastaleHenry Ford Health SystemPhase 1

sacituzumab govitecan (Trodelvy, Sacituzumab govetican)

Gastrointestinal Cancer · Gastrointestinal Cancer

#GastrointestinalCancer#ADC#Phase1#antibody-drug-conjugate#Henry
Trials 3Status Recruiting
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LCAR-G08 cells (LCAR-G08 cells)

Advanced Gastrointestinal Tumors · Advanced Gastrointestinal Tumors

#AdvancedGastrointestinalTumors#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
CGTLimited DatastaleIntima Bioscience, Inc.Phase 2

TIL (Tumor-Infiltrating Lymphocytes, Tumor-Infiltrating Lymphocytes (TIL))

Gastrointestinal Epithelial Cancer; Gastrointestinal Neoplasms · Gastrointestinal Epithelial Cancer

#GastrointestinalEpithelialCancer#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastalePeking UniversityPhase 2

regorafenib combined with envafolimab (regorafenib combined with envafolimab)

Metastatic Gastrointestinal Stromal Tumors (GIST) · MET

#MET#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting